Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.

From the perspective of the Canadian public healthcare payer, stiripentol is not cost effective at its current price at a willingness-to-pay threshold of $Can50,000. Funding stiripentol will be associated with important opportunity costs that bear consideration.